GeneVentiv Targeting Gene Therapies For Hemophilia, Pompe Disease

When Damon Race, a seasoned biopharmaceutical entrepreneur and investor based in Raleigh, set out to launch a new company, he didn’t have to look far to find the foundational technologies he needed. Although he initially explored a wide range of opportunities—reviewing between 30 and 40 potential assets across the country—his search ultimately led him back to his own backyard in North Carolina. In October 2020, Race decided to in-license a promising gene therapy developed just a short drive away at the University of North Carolina at Chapel Hill. Then, in April 2025, he expanded his portfolio by licensing a cutting-edge gene-editing therapy from Duke University, located in nearby Durham.

Explore how both institutions, situated within a half-hour’s drive from his base in Raleigh, provided Race with access to world-class innovations that aligned perfectly with his vision for the new venture.